164 related articles for article (PubMed ID: 26166221)
1. Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method.
Terrone C; Berruti A; Papotti M; Vavassori V; Sciarra A
Tumori; 2016 Oct; 102(5):514-520. PubMed ID: 26166221
[TBL] [Abstract][Full Text] [Related]
2. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
3. PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients.
Fersino S; Borghesi S; Jereczek-Fossa BA; Arcangeli S; Mortellaro G; Magrini SM; Alongi F;
Radiol Med; 2021 Mar; 126(3):460-465. PubMed ID: 32852750
[TBL] [Abstract][Full Text] [Related]
4. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.
Gómez-Caamaño A; González-San Segundo C; Henríquez I; Maldonado X; Zapatero A;
Clin Transl Oncol; 2019 Apr; 21(4):420-432. PubMed ID: 30293231
[TBL] [Abstract][Full Text] [Related]
5. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
[TBL] [Abstract][Full Text] [Related]
6. Should we involve patients more actively? Perspectives of the multidisciplinary team on shared decision-making for older patients with metastatic castration-resistant prostate cancer.
de Angst IB; Kil PJM; Bangma CH; Takkenberg JJM
J Geriatr Oncol; 2019 Jul; 10(4):653-658. PubMed ID: 30639265
[TBL] [Abstract][Full Text] [Related]
7. [Consensus on castration-resistant prostate cancer management in Spain.].
Alcaraz A; Martínez-Piñeiro L; Rodríguez A; Rubio J; Borque Á; Burgos J; Carballido J; Cózar JM; Crespo I; Esquena S; Gómez-Veiga F; López D; Miñana B; Morote J; Ribal MJ; Solsona E; Suárez JF; Unda M
Arch Esp Urol; 2017 Nov; 70(9):777-791. PubMed ID: 29099380
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.
Sternberg CN; Baskin-Bey ES; Watson M; Worsfold A; Rider A; Tombal B
BMC Urol; 2013 Nov; 13():58. PubMed ID: 24206580
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
Conteduca V; Caffo O; Lolli C; Aieta M; Scarpi E; Bianchi E; Maines F; Schepisi G; Salvi S; Massari F; Carrozza F; Veccia A; Chiuri VE; Campadelli E; Facchini G; De Giorgi U
Prostate; 2017 Jun; 77(9):1012-1019. PubMed ID: 28429372
[TBL] [Abstract][Full Text] [Related]
11. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Benidir T; Hersey K; Finelli A; Hamilton R; Joshua AM; Kulkarni G; Zlotta A; Fleshner N
Urol Oncol; 2018 May; 36(5):240.e13-240.e20. PubMed ID: 29454590
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation and diagnosis for castration resistant prostate cancer: CRPC].
Kamoto T
Nihon Rinsho; 2014 Dec; 72(12):2103-7. PubMed ID: 25518341
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
14. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
15. Understanding Prescribing Differences Between Urologists and Medical Oncologists in the Management of Advanced Prostate Cancer.
Demus T; Getzenberg RH; Nieder AM
Urol Pract; 2023 Jan; 10(1):90-97. PubMed ID: 37103443
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
[TBL] [Abstract][Full Text] [Related]
17. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
Fujimoto N
J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
[TBL] [Abstract][Full Text] [Related]
18. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer.
Ishibashi Y; Tobisawa Y; Hatakeyama S; Ohashi T; Tanaka M; Narita S; Koie T; Habuchi T; Nishimura S; Ohyama C; Yoneyama T
Prostate; 2014 Nov; 74(15):1521-9. PubMed ID: 25154914
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Shore ND; Drake CG; Lin DW; Ryan CJ; Stratton KL; Dunshee C; Karsh LI; Kaul S; Kernen K; Pieczonka C; Sieber P; Stewart C; Williams M; Concepcion RS
Prostate; 2020 Oct; 80(14):1159-1176. PubMed ID: 32779781
[TBL] [Abstract][Full Text] [Related]
20. [Management of a progressing prostate cancer: results of a national study].
Rozet F; Roupret M; Hennequin C; Massard C; Blanchard P; Le Moulec S
Prog Urol; 2017 May; 27(6):381-388. PubMed ID: 28392429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
